Search
EHA-SWG Scientific Meeting on New Molecular Insights and Innovative Management Approaches for Acute Lymphoblastic Leukemia
Dates: April 12-14, 2018
Location: Barcelona, Spain
Chair: N Gökbuget
Co-chairs: R Bassan, H Dombret, A Fielding, R Foà, D Hoelzer, JM Ribera
EHA and the EHA Scientific Working Group on Acute Lymphoblastic Leukemia are organizing their second EHA-SWG Scientific Meeting on Acute Lymphoblastic Leukemia.…
For mentors of applicants
As part of your support for the candidate applying for CBTH, the following is required from you:
Supervision and mentorship to be provided to the applicant during the CBTH award year.
EU funding calls for hematology
Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…
European Hematology Curriculum
Harmonization of hematology knowledge is part of EHA’s mission. The first step in harmonizing hematology training is to stipulate the required fields of knowledge, each with its recommended level of competence.
Read morePediatric Hematology
The SWG on Pediatric Hematology has several key goals for the next four years (2024–2026):
To further develop our role as the voice of pediatric hematology within EHA
To reach out to YEHA pediatric hematologists to develop educational material to underpin our…
SWG Committee
Current committee members
Konstanze Döhner, Germany (Chair (EHA Board member))
Dominique Bonnet, France (Vice-Chair)
Immacolata Andolfo, Italy
Igor Aurer, Croatia
Raul Cordoba, Spain
Hermann Einsele, Germany
Eleni Gavriilaki, Greece (Representative, Young EHA Committee)
Kirsten Gronbaek, Denmark (EHA Board)
Esther Oliva, Italy
Marc Raaijmakers, The Netherlands
Josef Vormoor, The Netherlands
Aim
The SWG Committee…
Uptake of CAR T cell therapy in Europe
Gene (editing) therapy continues to break ground in hematology, showing promising results in tackling severe blood cancers. Yet, its uptake in the European Union is slow, with few patients benefiting from it so far.
Read more